

## Use of Pneumococcal Vaccines (PPSV23, PCV13) for Adults 19 Years and Older

Risk Groups Recommended for PPSV23 (Pneumococcal Polysaccharide Vaccine)	PPSV23 Schedule
<b>Vaccinate persons aged 19-64 years:</b> <ul style="list-style-type: none"> <li>With asthma or who smoke cigarettes</li> </ul>	Persons with one or more of these risk factors should receive: <ul style="list-style-type: none"> <li>1 dose of PPSV23 between the ages of 2-64 years</li> <li>1 dose of PPSV23 at/after age 65 years</li> </ul> Use a minimum of 5 years between PPSV23 doses
<b>Vaccinate persons aged 2-64 years:</b> <ul style="list-style-type: none"> <li>With chronic cardiovascular disease (including congestive heart failure, cardiomyopathies), chronic pulmonary disease (including COPD and emphysema) or diabetes mellitus</li> <li>With alcoholism or chronic liver disease (including cirrhosis)</li> <li>Within environments or settings with identified increased risk</li> <li>Who have a cerebrospinal fluid (CSF) leak or cochlear implant<sup>1</sup></li> </ul>	Persons who are immunocompetent should receive: <ul style="list-style-type: none"> <li>1 dose of PPSV23 between the ages of 2-64</li> <li>1 dose of PPSV23 at/after age 65 years</li> </ul> Use a minimum interval of 5 years between PPSV23 doses  PCV13 is also indicated for persons with CSF leaks and cochlear implants (see adult recommendations below)
<b>Vaccinate persons aged 2-64 years:</b> <ul style="list-style-type: none"> <li>With functional or anatomic asplenia (including sickle cell disease and splenectomy)</li> <li>With immunocompromising conditions including HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndromes, congenital or acquired immunodeficiencies</li> <li>Receiving treatment using immunosuppressive drugs, including long-term systemic corticosteroids or radiation therapy</li> <li>Who have received solid organ transplantation</li> </ul>	Persons with asplenia or who are immunocompromised should receive: <ul style="list-style-type: none"> <li>2 doses of PPSV23 between the ages of 2-64 years</li> <li>1 dose of PPSV23 at/after age 65 years</li> </ul> Use a minimum interval of 5 years between PPSV23  PCV13 is also indicated for persons within one of these risk groups (see adult recommendations below)
Risk Groups Recommended for PCV13 (Pneumococcal Conjugate Vaccine)	PCV13 Schedule
<b>Vaccinate persons aged 19 years and older:</b> <ul style="list-style-type: none"> <li>Who have a CSF leak or cochlear implant<sup>1</sup></li> <li>With functional or anatomic asplenia (including sickle cell disease and splenectomy)</li> <li>With immunocompromising conditions including HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndromes, congenital or acquired immunodeficiencies</li> <li>Receiving treatment using immunosuppressive drugs, including long-term systemic corticosteroids or radiation therapy</li> <li>Who have received solid organ transplantation</li> </ul>	For all persons who are 19 years or older: <ul style="list-style-type: none"> <li>1 dose of PCV13<sup>2</sup></li> </ul> Preferred that PCV13 be given before any doses of PPSV23 <ul style="list-style-type: none"> <li>If no previous doses of PPSV23, give PCV13 first &amp; then give PPSV23 at least 8 weeks later.</li> <li>If one or more doses of PPSV23 have been given, there should be a minimum interval of 1 year between the last PPSV23 &amp; the PCV13<sup>3</sup></li> </ul> Continue to use a minimum interval of 5 years between two PPSV23 doses
Pneumococcal Vaccination for Persons Aged 65 Years and Older **	PCV13 and PPSV23 Schedule
<b>Routinely vaccinate persons aged 65 years or older:</b> <ul style="list-style-type: none"> <li>Who have never received 1 dose of PCV13<sup>2</sup></li> <li>Who have not received 1 dose of PPSV23 at/after age 65 years</li> </ul> <p>**Persons age 65 years or older who have a condition listed under "Risk Groups Recommended for PCV13" (i.e., asplenia, cochlear implant) should follow the interval schedule between PCV13 &amp; PPSV23 described in that section.</p>	Intervals for person 65 years or older who need both PCV13 and PPSV23 <sup>3</sup> : <ul style="list-style-type: none"> <li>Administer PCV13 first (preferred)</li> <li>Administer PPSV23 1 year later</li> <li>If PPSV23 was administered 1<sup>st</sup>, wait 1 year to give PCV13</li> <li>If one or more doses of PPSV23 was administered prior to age 65 years, ensure a minimum interval of 5 years after most recent dose of PPSV23</li> </ul>

<sup>1</sup>For purpose of pneumococcal vaccination, CSF leaks & cochlear implants are considered high-risk immunocompetent conditions

<sup>2</sup>If a previous dose of PCV13 has been administered, an additional dose is not recommended

<sup>3</sup>If both vaccines are recommended, administer at separate visits. PCV13 first (preferred) then PPSV23, ensuring recommended intervals

Resources: Use of PCV13 & PPSV23 in Adults with Immunocompromising Conditions, ACIP Recommendations, MMWR 61 (40) Oct. 12, 2012;

Updated Recommendations for Prevention of Invasive Pneumococcal Disease in Adults using PPSV23, MMWR 59(24) September 10, 2010; Use

of PCV13 and PPSV23 Among Adults aged 65 Years, MMWR 63(37) Sept 19, 2014 & Intervals Between PCV13 and PPSV23 Vaccines, MMWR

64(34) Sept. 4, 2015 Available at [www.cdc.gov/vaccines](http://www.cdc.gov/vaccines)